Capricor Aims for August 2026 FDA Decision on Duchenne Therapy
Event summary
- Capricor's Deramiocel BLA for Duchenne muscular dystrophy (DMD) is under FDA review with a PDUFA target action date of August 22, 2026.
- The HOPE-3 Phase 3 trial met primary and key secondary endpoints, showing statistical significance in PUL v2.0 and LVEF.
- Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits.
- Capricor's San Diego GMP manufacturing facility is operational to support potential commercial launch.
- Cash balance of approximately $318 million expected to support operations through 2027.
The big picture
Capricor is positioning itself for a potential regulatory milestone with Deramiocel, its lead candidate for Duchenne muscular dystrophy. The company's strategic focus on manufacturing readiness and financial stability underscores its ambition to transition from clinical-stage to commercial-stage. The broader biotech landscape is watching closely, as successful approvals in rare diseases can drive significant market opportunities and investor interest.
What we're watching
- Regulatory Outcome
- Whether the FDA will approve Deramiocel by the August 22, 2026 PDUFA date, given the positive Phase 3 trial results and additional late-breaking data.
- Commercial Readiness
- The pace at which Capricor can scale its manufacturing capabilities to meet potential demand following a Deramiocel approval.
- Pipeline Development
- How Capricor advances its StealthX™ exosome-based vaccine platform, with preliminary Phase 1 trial data expected in Q2 2026.
Related topics